Clinical Trials Directory

Trials / Unknown

UnknownNCT02838537

TRiptan Use and Serious Vascular Events in Elderly Over 65 Years

Status
Unknown
Phase
Study type
Observational
Enrollment
25,000 (estimated)
Sponsor
Assistance Publique Hopitaux De Marseille · Academic / Other
Sex
All
Age
65 Years
Healthy volunteers
Not accepted

Summary

This study will be conducted as a retrospective study of exposed and unexposed cohort of the French population included all beneficiaries aged 65 and older. Exposed patients will be matched to non exposed controls according age, gender and area of residence (ratio 1/4). Two exposed arms and two non exposed control arms will be planned. Triptan arm will be user of triptan defined as at least one recorded dispensing of any drug during the follow up, with no recorded of any of these drugs during the previous 6 months ("new or incident users"). Ergot arm will be user of ergot derivative defined as at least one recorded dispensing of any drug during the follow up, with no recorded of any of these drugs during the previous 6 months ("new or incident users"). This study involved data from the French National Health Insurance Information System (Système National d"Information Inter-Régimes de l"Assurance Maladie ; SNIIRAM) linked with the French hospital discharge database (Programme de Médicalisation des Systèmes d"Informations, PMSI). * The SNIIRAM is a vast national medico-administrative database representing the most part of the French population, allowing to identify and to describe precisely all medication dispensations (name of drug, date of dispensing and quantity) including triptans and other reimbursed medications. * The PMSI provides medical information about all patients admitted to hospital in France, including discharge diagnoses encoded according ICD-10, medical procedures and French diagnosis-related groups The research proposed is expected to provide an update and nationally-consolidated estimation of the cardiovascular risk is associated to triptans use in elderly population.

Conditions

Interventions

TypeNameDescription
DRUGExposure to Triptan
DRUGExposure to Ergot

Timeline

Start date
2015-11-01
Primary completion
2016-12-01
Completion
2017-05-01
First posted
2016-07-20
Last updated
2016-07-20

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT02838537. Inclusion in this directory is not an endorsement.